News Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:41:35 10/02/2026 GMT			5-day change	1st Jan Change
15.39 ^USD	+2.81%		+5.96%	-11.61%

01-29	Sector Update: Health Care Stocks Edge Higher Premarket Thursday	MT
01-29	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI

All News

02-09	Avacta appoints new chief scientific officer, plans clinical trials	AN
02-09	Avacta Therapeutics Announces Executive Changes	CI
01-30	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
01-30	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	AQ
01-29	Sector Update: Health Care Stocks Edge Higher Premarket Thursday	MT
01-29	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI
01-29	Summit Therapeutics Says US FDA Accepts BLA for Ivonescimab	MT
01-29	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	BU
01-13	AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says	MT
01-12	Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	CI
01-12	Summit Therapeutics Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09:45 AM
01-12	Summit Therapeutics, GSK Team up on Clinical Trial for Combination Cancer Therapy	MT
01-12	Summit Therapeutics Files Marketing Application for Lung Cancer Therapy	MT
01-12	Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)	BU
01-12	Summit Therapeutics Announces Clinical Trial Collaboration with GSK plc to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate	CI
01-12	Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	BU
01-10	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
01-06	Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	BU
12-17	Barclays Upgrades Summit Therapeutics to Equal Weight From Underweight, Adjusts Price Target to $18 From $16	MT
12-09	Akeso, Inc. Announces Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia	CI
12-05	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
12-03	Summit Therapeutics Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 02:10 PM
12-02	Summit Therapeutics Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 10:30 AM
11-18	Summit Therapeutics Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 03:30 PM
11-10	Summit Therapeutics Inc. Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 03:30 PM

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

All News

Filters